clinical trial · NCT07625293
DB-3Q for the Treatment of Medically Refractory Crohn's Disease
Direct Biologics, LLC·phase2·recruiting·n = 36
Crohn Disease (CD)DB-3QPlacebo
brief summary
This research study is studying DB-3Q as a possible treatment for medically refractory Crohn's disease. The purpose of this study is to research and evaluate safety and effectiveness of the administration of bone marrow mesenchymal stem cell (bmMSC) derived extracellular vesicles product, DB-3Q, the study drug for Crohn's disease.
started
Jun 1, 2026
primary completion
Jun 1, 2027
completion
Dec 1, 2027
last updated
Sep 1, 2026
official title
A Phase 2a Study of DB-3Q for the Treatment of Medically Refractory Crohn's Disease
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol